Patents by Inventor Robert R. Redfield

Robert R. Redfield has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Treatment agents for inhibiting HIV and cancer in HIV infected patients
    Patent number: 11364242
    Abstract: Methods are provided for treating HIV and cancer in a subject in need thereof by administering to the subject therapeutically effective amounts of an mTOR inhibitor. Other methods are provided for treating subjects infected with HIV by administering to the subject therapeutically effective amounts of the mTOR inhibitor INK128, GSK2126458, AZD2014 or Torin-2.
    Type: Grant
    Filed: September 24, 2019
    Date of Patent: June 21, 2022
    Assignee: UNIVERSITY OF MARYLAND, BALTIMORE
    Inventors: Robert R. Redfield, Alonso Heredia, Charles Davis, Ronald Gartenhaus, Edward A. Sausville
  • Treatment Agents for Inhibiting HIV and Cancer in HIV Infected Patients
    Publication number: 20200016160
    Abstract: Methods are provided for treating HIV and cancer in a subject in need thereof by administering to the subject therapeutically effective amounts of an mTOR inhibitor. Other methods are provided for treating subjects infected with HIV by administering to the subject therapeutically effective amounts of the mTOR inhibitor INK128, GSK2126458, AZD2014 or Torin-2.
    Type: Application
    Filed: September 24, 2019
    Publication date: January 16, 2020
    Applicant: University of Maryland, Baltimore
    Inventors: Robert R. Redfield, Alonso Heredia, Charles Davis, Ronald Gartenhaus, Edward A. Sausville
  • TREATMENT AGENTS FOR INHIBITING HIV AND CANCER IN HIV INFECTED PATIENTS
    Publication number: 20160339030
    Abstract: Methods are provided for treating HIV and cancer in a subject in need thereof by administering to the subject therapeutically effective amounts of an mTOR inhibitor. Other methods are provided for treating subjects infected with HIV by administering to the subject therapeutically effective amounts of the mTOR inhibitor INK128, GSK2126458, AZD2014 or Torin-2.
    Type: Application
    Filed: May 19, 2016
    Publication date: November 24, 2016
    Applicant: University of Maryland, Baltimore
    Inventors: Robert R. Redfield, Alonso Heredia, Charles E. Davis, Ronald B. Gartenhaus, Edward A. Sausville
  • Compositions for down-regulation of CCR5 expression and methods of use thereof
    Patent number: 7863242
    Abstract: The present invention relates to the downregulation of surface receptor CCR5 expression through manipulation of the cell cycle in activated lymphocytes by administering a composition that arrests the G1 phase of the cell cycle, thereby reducing receptor sites for entry of HIV into T cells, and thus, the effects of HIV. Further, compositions are disclosed that include at least one G1 phase arresting agent and at least one antiviral agent, wherein the combination of agents synergistically enhances the activity of the antiviral agent.
    Type: Grant
    Filed: November 16, 2005
    Date of Patent: January 4, 2011
    Assignee: University of Maryland, Baltimore
    Inventors: Robert R. Redfield, Anthony Amoroso, Charles E. Davis, Alonso Heredia
  • Compositions for treating viral infections, and methods therefor
    Patent number: 6479466
    Abstract: Methods and combinations of an agent that promotes DNA synthesis in a virally-targeted cell and a nucleoside analogue having antiviral activity are provided for treating a viral infection in a subject in need thereof. Such compositions are particularly effective where the subject has resistance to a nucleoside analogue, where the subject has resting cellular reservoirs of such a virus, or to induce a post-treatment period of replication incompetence of such a virus.
    Type: Grant
    Filed: August 11, 2000
    Date of Patent: November 12, 2002
    Assignees: University of Maryland, University of Maryland Biotechnology Institute
    Inventors: Robert R. Redfield, Charles E. Davis, Jr., Alonso Heredia